Jaypirca

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

News

Lilly gets approval for earlier use of Jaypirca in CLL

Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.

News

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

FDA clears first all-oral combo for first-line CLL treatment

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Lilly gets approval for earlier use of Jaypirca in CLL

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly breaks new ground for BTK class with Jaypirca approval

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Jaypirca

Editor's Picks